Condition: Recurrent Rectal Cancer · Sponsor: Catharina Ziekenhuis Eindhoven
This is a multicentre, open-label, parallel arms, phase IIII study that randomises patients with locally recurrent rectal cancer in a 1:1 ratio to receive either induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery (experimental arm) or neoadjuvant chemoradiotherapy and surgery alone (control arm)
This description comes directly from the study's public registry record.
Stefi Nordkamp, MD · 0031 40 2398858 · stefi.nordkamp@catharinaziekenhuis.nl
Floor Piqeur, MD · 0031 40 2397152 · floor.piqeur@catharinaziekenhuis.nl
Always discuss trial participation with your own doctor first.
| UZ Gent | Ghent, Belgium | Not Yet Recruiting |
| Amsterdam UMC | Amsterdam, Netherlands | Recruiting |
| Antoni van Leeuwenhoek | Amsterdam, Netherlands | Recruiting |
| Catharina Hospital | Eindhoven, Netherlands | Recruiting |
| University Medical Centre Groningen | Groningen, Netherlands | Recruiting |
| Leids University Medical Centre | Leiden, Netherlands | Recruiting |
| Haaglanden Medical Centre | Leidschendam, Netherlands | Recruiting |
| Maastricht University Medical Centre | Maastricht, Netherlands | Recruiting |
| Erasmus Medical Centre | Rotterdam, Netherlands | Recruiting |
| Oslo Universitetssykehus | Oslo, Norway | Not Yet Recruiting |
| Instituto Portugues de Oncologia de Lisboa Francisco Gentil, E.P.E. | Lisbon, Portugal | Not Yet Recruiting |
| Sahlgrenska Universitetssjukhuset | Gothenburg, Sweden | Not Yet Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04389086